Literature DB >> 1977531

Ten-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS)

W J Rogers1, C J Coggin, B J Gersh, L D Fisher, W O Myers, A Oberman, L T Sheffield.   

Abstract

Quality of life indexes were assessed in 780 patients 10 years after randomization to medical therapy (n = 390) or coronary artery bypass graft surgery (n = 390) in the Coronary Artery Surgery Study. At 10 years, mortality was 21.8% in the medical group and 19.2% in the surgical group (p = NS), and 144 (37%) of the medical group had undergone surgery because of increasing chest pain. At study entry, 22% of medical and surgical patients were angina free; at 1 and 5 years after entry, the frequency of asymptomatic patients was 66% and 63% in the surgical group and 30% and 38% in the medical group. However, by 10 years after entry, the proportion of patients free of angina had fallen to 47% in the surgical group and to 42% in the medical group. Activity limitation and use of beta-blockers and long-acting nitrates were less in the surgical than the medical group at 1 and 5 years after entry but little different from the medical group at 10 years after entry. Throughout follow-up, recreational status, employment status, frequency of heart failure, use of other medications, and hospitalization frequency were similar between the two groups. Thus, indexes of quality of life such as angina relief, increased activity, and reduction in use of antianginal medications initially appear superior in patients with stable manifestations of ischemic heart disease assigned to surgery, but by 10 years after entry, these advantages are much less apparent. Although the observed similarities of the medically and surgically assigned groups at 10 years reflect return of symptoms in the surgical group to some extent, a more important explanation is the performance of late surgery in a large proportion of the medically assigned patients, rendering them asymptomatic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977531     DOI: 10.1161/01.cir.82.5.1647

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Effective management of stable angina.

Authors:  M Petticrew; M Sculpher; J Kelland; R Elliott; D Holdright; M Buxton
Journal:  Qual Health Care       Date:  1998-06

2.  Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy.

Authors:  Eric J Velazquez; Judson B Williams; Eric Yow; Linda K Shaw; Kerry L Lee; Harry R Phillips; Christopher M O'Connor; Peter K Smith; Robert H Jones
Journal:  Ann Thorac Surg       Date:  2012-02       Impact factor: 4.330

3.  Determinants of an impaired quality of life five years after coronary artery bypass surgery.

Authors:  J Herlitz; I Wiklund; K Caidahl; B W Karlson; H Sjöland; M Hartford; M Haglid; T Karlsson
Journal:  Heart       Date:  1999-04       Impact factor: 5.994

Review 4.  Current Indications for Stenting: Symptoms or Survival CME.

Authors:  Suzanne V Arnold
Journal:  Methodist Debakey Cardiovasc J       Date:  2018 Jan-Mar

5.  Predictors of Quality of Life Improvement after 2 Years of Coronary Artery Bypass Surgery.

Authors:  Vladan Peric; Radojica Stolic; Aleksandar Jovanovic; Rade Grbic; Bratislav Lazic; Sasa Sovtic; Milorad Borzanovic
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-08-01       Impact factor: 1.520

Review 6.  Review of quality-of-life evaluations in patients with angina pectoris.

Authors:  A Gandjour; K W Lauterbach
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 7.  Surgical, medical, and percutaneous therapies for patients with multivessel coronary artery disease.

Authors:  Murtuza J Ali; Ravin Davidoff
Journal:  Curr Cardiol Rep       Date:  2006-07       Impact factor: 2.931

Review 8.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

Review 9.  Challenges with Evidence-Based Management of Stable Ischemic Heart Disease.

Authors:  Amit V Patel; Sripal Bangalore
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

Review 10.  Review of available instruments and methods for assessing quality of life in anti-anginal trials.

Authors:  B D Bliven; C P Green; J A Spertus
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.